Lineage Cell Therapeutics Inc

(a) On March 6, we and each of Brian M. Culley, Jill A. Howe, and George A. Samuel III, each of whom is one of our executive officers, entered into an amendment to their respective employment agreements. Under the terms of each of their employment agreements before they were amended, if their employment was terminated by us without cause (as defined in their employment agreements) or if they resigned for good reason (as defined in their employment agreements), among other benefits payable to them, we would pay the applicable executive a specified percentage of their target bonus for the year in which their employment was terminated. Under the terms of the amendment, (1) if the applicable executive’s target bonus for the year in which their employment is terminated has not been set at the time their employment is terminated, then the amount of their target bonus for the immediately preceding year will be deemed to be the target bonus for the year in which their employment is terminated; and (2) if the applicable executive has not been paid their bonus for the immediately preceding year at the time their employment is terminated solely because executive’s employment is terminated before the date on which such bonus otherwise would be paid, they will also receive a payment equal to 100% of the target bonus of such preceding year.

(b) During the period from October 1, 2023 to December 31, 2023, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).